JOURNAL ARTICLE

Researchers from Medical University of Silesia Report Recent Findings in Schizophrenia (Modulation of glycine transporters as a novel therapeutic strategy in neuropsychiatry).

  • Published In: Mental Health Weekly Digest, 2025. P. 4095 1 of 2

  • Database: Psychology Source 2 of 2

Abstract

The article focuses on recent research from Katowice, Poland, regarding the role of glycine transporters (GlyTs) in treating schizophrenia and other mental health disorders. Glycine functions as an inhibitory neurotransmitter and a co-agonist at N-methyl-D-aspartate receptors (NMDARs), with GlyT1 and GlyT2 regulating its levels in the central nervous system. The study highlights the potential of GlyT1 inhibitors, particularly sarcosine, in enhancing NMDAR function and addressing symptoms of schizophrenia and depression, while also noting challenges in clinical application. Future research is suggested to utilize imaging biomarkers and advanced pharmacological tools to maximize the therapeutic benefits of GlyTs. [Extracted from the article]

Additional Information

  • Source:Mental Health Weekly Digest. 2025/10, p4095
  • Document Type:Article
  • Subject Area:Health and Medicine
  • Publication Date:2025
  • ISSN:1543-6616
  • Accession Number:188850659
  • Copyright Statement:Copyright of Mental Health Weekly Digest is the property of NewsRx and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.